CTOs on the Move

Molecular Designs

www.moleculardesigns.com

 
Better products. Better service. MOLECULAR DESIGNS Molecular Designs is a team of doctors and scientists working to advance molecular diagnostics. We do this by developing, producing, and supplying multiplex assays for molecular testing ...
  • Number of Employees: 0-25
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Similar Companies

QIAGEN

QIAGEN is a German provider of sample and assay technologies for molecular diagnostics, applied testing, academic and pharmaceutical research.

Chinook Therapeutics

Kidney diseases are a severe and growing problem worldwide, with a lack of effective treatments often leading to dialysis, transplantation and high costs to health care systems. In the U.S. alone, kidney diseases affect an estimated 37 million people and account for over $100 billion in annual costs.

Seres Therapeutics

Seres Therapeutics is a clinical stage biotherapeutic company focused on discovering and developing Ecobioticâ„¢ therapeutic products, novel drugs to treat important diseases by targeting the underlying biology of the human microbiome. Founded by Flagship VentureLabs, Seres is pioneering the first therapeutics that catalyze a shift to health by augmenting the biology of the microbiome. Current candidates span infectious, metabolic, and inflammatory diseases.

Mohawk Shared Services

Mohawk Shared Services is a Burlington, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Pharmaceutical Product Development

PPD is a leading global contract research organization providing drug discovery, development, lifecycle management and laboratory services. Our clients and partners include pharmaceutical, biotechnology, medical device, academic and government organizations. With offices in 46 countries and approximately 13,000 professionals worldwide, PPD applies innovative technologies, therapeutic expertise and a commitment to quality to help clients and partners accelerate the delivery of safe and effective therapeutics and maximize the returns on their R&D investments.